Interview with Worwick Anderson, NHMRC,
Would you begin by outlining the key milestones & achievements of the NHMRC in the past four years? The first point is the development of our initiatives on an international…
Address: Level 1, 16 Marcus Clarke Street, Canberra,Australia
Tel: +61 2 6217 9000
The NHMRC is Australia’s NIH equivalent, being the big government funding body for health and medical research. We have always had in our portfolio a full range of health and medical research. Some funding bodies like the UKMRC are more biomedical, but the NHMRC has always been concerned with public health and health services research, so it’s a very broad portfolio. The NHMRC is more than a funding body, and strives to improve the lives of all Australians. For example, the organization publishes evidence-based guidelines for clinical practice and public health. An example of the latter is the current work being completed in finalizing safe alcohol-drinking guidelines, around which there is some controversy as we speak, because the message from science and what the public would like to believe do not always align.
The NHMRC also manages research and clinical ethics systems for Australia, publishing guidelines in this regard. Overall, it’s a fantastic organization of great importance to the health and wealth of the country. The NHMRC was a part of the Department of Health until July of 2006, when, coinciding with my arrival, we became an independent government body within the health portfolio, reporting directly to the Minister, which gives us all sorts of opportunities. Other aspects of the NHMRC portfolio include acting as the body under the Australian parliament act around stem cells, to issue licensing for cloning and embryo experimentation.
Would you begin by outlining the key milestones & achievements of the NHMRC in the past four years? The first point is the development of our initiatives on an international…
Your distinguished career in health research leadership and management has seen you through a variety of prestigious positions, not to mention the Order of Australia. Most recently you were appointed…
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive…
2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC).…
One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our…
What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines, Nycomed is also experiencing the…
New Government health priorities and policies, highlighting those concerning preventive health. The Rudd Labor Government’s goal in health is to create a modern health system designed for the health needs…
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
Pharmacor is one of the newest entities on the Australian pharmaceutical market. Would you please introduce the company to let Pharmaceutical Executive readers understand more about the Pharmacor story? Pharmacare…
Would you please introduce the PBAC and the role it plays in Australia’s pharmaceutical sector? The Pharmaceutical Benefits Advisory Committee (PBAC) is a statutory committee of the Australian government which…
Molteni was created in 1892 and progressively developed a strong manufacturing base, a very active R&D department and a growing international presence. Could you introduce the story behind such achievements?…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the association that represents the country’s research-based pharmaceutical industry. With approximately 50 members, the organization…
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
See our Cookie Privacy Policy Here
